Morphine is among the most prevalent analgesics prescribed for chronic pain. However, prolonged morphine treatment results in the development of analgesic tolerance. An abundance of evidence has accumulated indicating that CNS glial cell activity facilitates pain transmission and opposes morphine analgesia. While the midbrain ventrolateral periaqueductal gray (vlPAG) is an important neural substrate mediating pain modulation and the development of morphine tolerance, no studies have directly assessed the role of PAG--glia. Here we test the hypothesis that morphine--induced increases in vlPAG glial cell activity contribute to the development of morphine tolerance. As morphine is primarily consumed for the alleviation of severe pain, the influence of persistent inflammatory pain was also assessed. Administration of morphine, in the absence of persistent inflammatory pain, resulted in the rapid development of morphine tolerance and was accompanied by a significant increase in vlPAG glial activation. In Perspective The development of morphine tolerance represents a significant impediment to its use in the management of chronic pain. We report that morphine tolerance is accompanied by increased glial cell activation within the vlPAG, and that the presence of a persistent pain state prevented vlPAG glial activation and attenuated morphine tolerance.
Introduction
Chronic pain, defined as pain lasting more than 3--6 months, will affect more than one in three Americans at some point in their life 64, 66 . Although morphine is one of the most commonly prescribed analgesics 76 , secondary side effects (e.g., tolerance) limit its efficacy for long--term chronic pain treatment 8, 28, 48, 49 . In the absence of pain, morphine tolerance, defined as the requirement for steadily larger doses of opioids to achieve the same analgesic effect, develops quite rapidly 19, 48, 54 . In contrast, clinical studies have consistently reported that the latency to develop morphine tolerance is increased in chronic pain sufferers, although dose escalation is eventually required for the maintenance of analgesic efficacy 77 . Dose escalation leads to increased risk of developing additional negative side effects, including anti--analgesia, addiction, withdrawal, and respiratory depression 76 , and is not always sufficient to overcome tolerance and reinstate analgesic efficacy 77 . As over 90% of chronic pain sufferers are treated with opioids 76 , including morphine, elucidation of the mechanisms by which morphine tolerance develops warrants investigation. The midbrain ventrolateral periaqueductal gray (vlPAG) and its descending projections to the rostral ventromedial medulla (RVM) and spinal cord, comprises an important neural circuit for both endogenous and exogenous opioid--mediated analgesia 4--7, 24 . In rats, chronic subcutaneous injections of morphine result in tolerance to subsequent doses of morphine, an effect that is eliminated by intra--vlPAG injections of the opioid receptor antagonist naltrexone 42 . In addition, chronic intra--vlPAG injections of morphine induce tolerance, and this effect remains when the RVM, the primary downstream target of the PAG, is inhibited with the GABA agonist muscimol 42 . An abundance of evidence has accumulated indicating that systemic morphine administration activates glial cells, including microglia and astrocytes 31, 51, 52, 60, 70, 75, 84 . Song and Zhou (2001) reported that chronic morphine administration results in the activation of astrocytes within the cingulate cortex, hippocampus and spinal cord, and that blockade of glial activation within the spinal cord attenuates the development of morphine tolerance. Since then, a myriad of studies have been published implicating glia activation in the development of morphine tolerance 84, 85 and pain facilitation 11, 61, 82 . While it is clear that the activation of microglia and astrocytes contribute to the development of morphine tolerance, no studies have examined the role of activated glia within the PAG, a primary site of morphine action. Similarly, the influence of a persistent inflammatory pain state on PAG glial cell activation has not been
assessed. The present study tested the hypothesis that morphine--induced increases in vlPAG glial cell activity contribute to the development of morphine tolerance, and that persistent inflammatory pain alters this activation, resulting in the attenuation of morphine tolerance.
Materials and Methods

Subjects
Weight--matched (250--350g) male Sprague Dawley rats (Charles River, Wilmington, MA) were pair--housed on a 12:12 hour light: dark cycle. Access to food and water was available ad libitum throughout the experiments except during behavioral testing. All studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia State University, and performed in strict compliance with Ethical Issues of the International Association for the Study of Pain (IASP) and National Institute of Health (NIH). All efforts were made to reduce the number of animals used in these experiments and to minimize any possible suffering by the animal.
Persistent Inflammatory Hyperalgesia
In a subset of animals, persistent inflammatory hyperalgesia was induced by injection of complete Freund's adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl), suspended in an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw as previously described 46, 48, 81 . As intraplantar saline administration results in a short--term inflammatory response, control animals were restrained in a similar manner but did not receive an intraplantar injection.
Experiment 1: Influence of Persistent Inflammatory Pain on Morphine Tolerance
Twenty--four hours following intraplantar CFA injection or handling, animals were administered morphine (5 mg/kg, sc; NIDA) or saline (1 ml/kg, sc) once a day for three consecutive days (CFA+Morphine; CFA+Saline; Handled+Morphine; Handled+Saline). The 5 mg/kg dose was chosen based on our previous studies demonstrating this to be the 50% effective dose (ED 50 ) for systemic morphine in male rats 47, 53, 81 
Behavioral data analysis and presentation
Behavioral data are expressed in raw seconds. Paw withdrawal latency data were analyzed using repeated measures ANOVA for significant main effect of pain (CFA or handled) and treatment (morphine or saline) across dose. Pre--planned t--tests were used to determine specific group and dose differences when a significant main effect was observed. All values are reported as Mean + S.E.M.; p< 0.05 was considered statistically significant.
Experiment 2: Anatomical Assessment of Morphine Tolerance
Twenty--four hours following intraplantar CFA or handling, animals were administered morphine (5 mg/kg; sc) or saline (1 ml/kg; sc) once a day for three consecutive days as described above (CFA+Morphine, CFA+Saline, Handled+Morphine, Handled+Saline). One hour following the last injection of morphine or saline, animals were given a lethal dose of Nembutal (160 mg/kg; i.p.) and transcardially perfused with 250 ml of 0.9% sodium chloride containing 2% sodium nitrite as a vasodilator to remove blood from the brain. Immediately following blood removal, 300 ml of 4% paraformaldehyde in 0.1M phosphate buffer containing 2.5% acrolein (Polysciences Inc.;
Warrington, PA) was perfused through the brain as a fixative. A final rinse with 250 ml of sodium chloride/sodium nitrite solution was perfused through the brain to remove any residual acrolein. Brains were removed and placed in a 30% sucrose solution and stored at 4°C until sectioning. To examine the acute effects of morphine on vlPAG glia activation, a separate group of animals received one sc injection of morphine (or saline) and were sacrificed 1 or 24 hours later. A separate group of animals (CFA+Morphine, CFA+Saline, Handled+Morphine, Handled+Saline) were decapitated immediately following treatment for western blot analysis.
Brains were removed, flash frozen in 2--methyl--butane on dry ice, and stored at --80°C.
Immunohistochemistry
Hallmarks of glial cell activity include increased cytokine release that correlates with increased expression of the protein markers glial fibrillary acetic protein (GFAP; astrocytes), and CD--11b
(OX--42; microglia) 60 . Further, increased glial cell activity is evidenced by a profound shift in morphology that can be easily visualized using immunohistochemistry for GFAP and OX--42 16 .
Perfused brains were sectioned into 25µm coronal sections with a Leica 2000R freezing microtome and stored free--floating in cryoprotectant--antifreeze solution 44 at --20°C. A 1:6 series through the rostrocaudal axis of each brain was processed for GFAP and OX--42 immunoreactivity using standard immunohistochemical techniques 56 . Briefly, sections were rinsed extensively in potassium phosphate--buffered saline (KPBS) immediately followed by a 20--minute incubation in 1% sodium borohydride. The tissue was then incubated in primary antibody solution (rabbit anti--GFAP 1:5,000 or rabbit anti--OX42 1:1000; Abcam) in KPBS containing 1.0% Triton--X for one hour at room temperature followed by 48 hours at 4°C. After rinsing with KPBS, the tissue was incubated for one hour in secondary antibody (biotinylated IgG goat anti--rabbit 1:600), rinsed with KPBS, and then incubated for one hour in an avidin-- 
Western blotting
Flash frozen brains were sectioned at 300µm on a cryostat (Leica, Buffalo Grove, IL) and mounted onto slides. One--millimeter bilateral micropunches were taken from 6 levels for the vlPAG (Bregma --8.52, --8.28, --7.92, --7.68, --7.20, and --6.96) 58 and 6 levels of the superior colliculus (Bregma --7.68, --7.20, --6.96, --6.60, --6.24, and --5.80) 58 , and homogenized in a 10mM
HEPES buffer (pH 7.2). Equal amounts of protein (2µg) along with a standard marker (Bio--Rad, Hercules, CA) were run at 100V for 2 hours through 10% Tris--HCl polyacrylamide gels (Bio--Rad, Hercules, CA), and electro--transferred at 4°C on ice at 250mA for 2 hours onto PVDF membranes (0.2µm pore size; Bio--Rad, Hercules, CA). Membranes were blocked with 5% milk in TBS--Tween 20 (1%) at 4°C overnight, and probed with rabbit anti--GFAP primary antibody
(1:300,000; Abcam) in 2% milk/TBS--Tween 20 (1%) for 3 hours at room temperature followed by a 30 minute incubation in HRP--conjugated goat anti--rabbit secondary (1:5000; Abcam) in 2% milk/TBS--Tween 20 (1%). Rabbit anti--β−actin primary (1:10,000; Novus Biologicals) was included as a control for protein loading. Membranes were stripped and reprobed with mouse anti--rat CD11b (OX--42, 1:700; Serotec) followed by HRP--conjugated goat anti--mouse (OX--42;
1:5000; Abcam) and HRP--conjugated goat anti--rabbit (β--actin; 1:5000; Abcam) secondaries.
Anatomical data analysis and presentation
Levels of GFAP and OX--42 immunoreactivity in the vlPAG were compared across treatment groups using semi--quantitative densitometry as previously described 43, 48 . To determine if the observed changes in glia activation were limited to the vlPAG, sections through the superior colliculus (SC), a region containing a high density of µ opioid receptors (MOR) but not implicated in opioid modulation of pain, were also analyzed. 12--bit grayscale images that included the region of interest (ROI) were captured using a QImaging Retiga EXi CCD camera (Surrey, BC, Canada) and iVision Image analysis software (Biovision Technologies, Exton, PA).
Grayscale values for each image were inverted so that higher values were representative of increased staining levels. Images of three slices through each ROI for each animal were analyzed and data sampled unilaterally. Data sampling occurred by using the drawing tools in iVision to outline the ROI and using the "measure" function to determine an average grayscale pixel value for the outlined area. ROI measures were corrected for nonspecific binding by subtraction of background measure taken from gray matter adjacent to the ROI. Data were analyzed across 3 representative levels through the rostral--caudal axis of the vlPAG (Bregma --7.08, --7.68, and --8.30) 58 and superior colliculus (Bregma --7.68, --6.24, and --5.80) 58 as previously described 48 . Densitometry values are presented as the mean + S.E.M. density of immunoreactivity. Data were analyzed using an ANOVA to determine significant main effects of treatment (morphine, saline) and pain (CFA, handled). Fisher's post hoc tests were used to determine specific group differences when a significant main effect was observed; p < 0.05 was considered statistically significant. For Western blots, band intensities for tissue from the vlPAG and superior colliculus were visualized at 55kD (GFAP) and 160kD (CD11b), and quantified using ImageJ (NIH, USA) analysis software, as a relative intensity of GFAP or CD11b band divided by the intensity of the β−actin band. Data are expressed as the mean ratio + S.E.M of protein of interest/β−actin. Data were analyzed for significant main effects of treatment (morphine, saline) and pain (CFA, handled) using an ANOVA, and Fisher's HSD was used for post--hoc analysis; p < 0.05 was considered statistically significant.
Results
Experiment 1: Persistent Peripheral Inflammation Attenuated Morphine Tolerance
To assess the initial analgesic potency of morphine, and the degree and time course for development of morphine tolerance, paw withdrawal latencies (PWL) were determined for both the injured (ipsilateral; right) and uninjured (contralateral; left) hindpaws at baseline, and 
Assessment of morphine tolerance
Morphine tolerance, assessed on Day 5 using a cumulative dosing paradigm, was only observed in non--CFA treated animals. As shown in Figure 2 , the antinociceptive potency of morphine was significantly decreased in both the ipsilateral and contralateral hindpaw of uninjured animals that received 3 consecutive days of morphine (Handled+Morphine) as compared with uninjured animals that received saline (Handled+Saline; Figures 2A and C) . Indeed, animals that received 3 days of saline reached 100% maximum possible analgesia (MPE) at the 8 mg/kg dose. In contrast, 100% MPE was not noted until the 18 mg/kg dose in animals that received 3 prior days of morphine. Neither the antinociceptive nor the antihyperalgesic potency of morphine was different in CFA+Morphine treated animals as compared with CFA+Saline treated animals ( Figures 2B and D) indicating lack of tolerance development. Indeed, no differences in PWLs produced by morphine were noted for all doses tested. Together these data indicate that persistent inflammatory pain attenuates the development of tolerance to morphine.
As glia activation in the spinal cord has been implicated in the development of morphine tolerance, the next series of experiments examined if glia were similarly activated within the vlPAG, and if persistent inflammatory pain altered their activation.
Experiment 2: Morphine Tolerance is Associated with Increased Glial Cell Activation in the vlPAG
Increased activity of astrocytes, as evidenced by an increase in GFAP immunoreactivity, was only observed in non--CFA treated animals that received morphine (Handled +Morphine, Figure   3B ). A representative example of vlPAG GFAP staining in animals administered CFA+Morphine versus Handled+Morphine is shown in Figure 3A . Western blots confirmed increased activity of astrocytes, as evidenced by an increase in relative band intensity of GFAP/ β--actin, was only observed in non--injured animals that received morphine (Handled+Morphine, Figure 3C ).
Similar to what was noted for astrocytes, microglia activity, as evidenced by OX--42 immunoreactivity, was significantly increased in animals that received morphine in the absence of pain (Handled+Morphine, Figure 4B ). A representative example of vlPAG OX--42 staining in animals administered CFA+Morphine versus Handled+Morphine is shown in Figure  4A . A trend towards increased activity of microglia, as evidenced by an increase in relative band intensity of OX--42/β--actin, was only observed in animals that received morphine in the absence of pain (Handled+Morphine, Figure 4C) ; however, it did not reach statistical significance. Peripheral inflammation induced by intraplantar CFA did not illicit significant increases in vlPAG glial cell activity ( Figures 3 and 4) . Importantly, one injection of morphine (5 mg/kg) was not sufficient to alter vlPAG GFAP ( Figure  5A ) or OX--42 levels (
Figure 5B 
Discussion
The present experiments tested the hypothesis that vlPAG glial cell activity contributes to the development of morphine tolerance. Clinical studies indicate that chronic pain attenuates the development of morphine tolerance 37, 77 ; however, animal studies have yielded variable results 35, 65, 78 . Therefore, the impact of persistent inflammatory hyperalgesia on morphine tolerance development and glial activation were also investigated. Here we report that (1) short--term daily administration of an ED 50 dose of morphine was sufficient to induce morphine tolerance; (2) persistent inflammatory pain induced by intraplantar CFA significantly attenuated morphine tolerance; and (3) increased vlPAG microglia and astrocyte activity was only observed in those animals made tolerant to morphine. Together, these data suggest a potential role for vlPAG microglia and astrocytes in the development of morphine tolerance, and suggest that persistent inflammatory pain attenuates morphine tolerance by inhibiting morphine--induced vlPAG glial cell activation.
Increases in vlPAG microglia and astrocyte activity correlate with the development of morphine tolerance
Many mechanisms have been proposed to account for opioid tolerance, including decoupling, internalization and/or down--regulation of µ opioid receptors 67, 68 , upregulation of NMDA receptor function 1--3 , down--regulation of glutamate transporters 9, 59 , and production of nitric oxide (a known mediator of NMDAR function) 84 . These mechanisms were all thought to implicate some form of 'neuronal adaptation' 84 . However, it is becoming increasingly clear that activated glia mediate many of these 'neuronal adaptations' that contribute to morphine tolerance 84 . Consistent with previous reports, here we find that tolerance to morphine developed rapidly in the absence of pain 41, 42, 48 . Indeed, one ED 50 dose of morphine (5 mg/kg) injected subcutaneously for three days was sufficient to induce behaviorally defined tolerance.
Paralleling the development of tolerance, GFAP and OX--42 protein levels increased significantly within the vlPAG, suggesting the activation of astrocytes and microglia, respectively.
A large body of evidence has accumulated implicating opioids as activators of spinal astrocytes and microglia 31, 60, 63, 86 . In both mice and rats, morphine increases spinal GFAP and OX--42 protein levels, 20, 33 as well as glially derived proinflammatory cytokines 32, 63 . Inhibition of spinal glia or cytokine release increases the analgesic efficacy of morphine 32, 63 , and attenuates morphine tolerance 31, 51, 52, 60, 70 . Our novel findings in the vlPAG parallel the data from studies of spinal cord glia, and indicate that supraspinal glial cell activity may also contribute to the development of morphine tolerance.
Under basal conditions glia survey the environment for pathogens, debris, and regulate ion and neurotransmitter levels in the synapse to modulate neuronal excitability 86 . The activation of glia results in the release of excitatory substances that oppose morphine analgesia (e.g., proinflammatory cytokines) 86 . Glial release of cytokines increases with chronicity of morphine administration 84 , making these excitatory substances key players in the development of morphine tolerance. Glially--derived cytokine release, particularly tumor necrosis factor alpha (TNFα) and interleukin--1 beta (IL--1β) , results in increased density and conductance of neuronal AMPA 57, 71 and NMDA 79 receptors, decreased astrocytic glutamate transporter proteins (GLT--1, GLAST) 86 , and down--regulation of neuronal GABA receptors 71 . These cytokine--induced changes, among others 39, 55 , effectively increase neuronal excitability. Morphine binds to neuronal µ opioid receptors (MOR) in the vlPAG that are primarily located on GABAergic neurons 14, 18, 38 ;
MOR binding in the vlPAG disinhibits GABAergic PAG--RVM projection neurons 25 , resulting in the net excitation of the PAG--RVM--spinal cord descending pain modulatory circuit. Glial--induced increases in the excitability of vlPAG MOR--containing neurons may act to alter the inhibitory properties of morphine, thereby decreasing analgesic efficacy and contributing to the development of morphine tolerance.
Persistent inflammatory pain prevented morphine--induced increases in vlPAG glial cell activity and attenuated the development of morphine tolerance
The results of the present study demonstrate that the presence of persistent pain alters both the development of morphine tolerance and morphine--induced vlPAG glial cell activation. The finding that persistent peripheral inflammation attenuates morphine tolerance is consistent with the clinical literature demonstrating that opioid tolerance is attenuated in chronic pain sufferers 17, 23, 26 . Indeed, clinical studies have repeatedly shown that morphine tolerance develops most robustly in those individuals consuming morphine in the absence of pain 19, 54 . In the present study, male rats given CFA 24 hours before the 3--day morphine administration regimen showed significant increases in analgesia to all challenge doses of morphine, as compared with non--injured animals. Several factors may contribute to the pain--induced attenuation in morphine tolerance. First, morphine, given in conjunction with peripheral inflammation, failed to illicit the increases in vlPAG microglia and astrocyte activity observed in non--CFA treated animals given morphine. Indeed, peripheral inflammatory pain blocked both morphine tolerance and morphine--induced glial cell activation within the vlPAG. As glia are not activated, no cytokine release would be expected, and, therefore, no net change in neuronal excitability. Alternatively, cannabinoids, which are released within the PAG during peripheral pain 80 , have been shown to influence both glial activity and morphine analgesia. Cannabinoid receptor is robustly expressed within the vlPAG, with approximately 32% of cannabinoid receptor 1 (CB1) expressing neurons also expressing µ opioid receptor 88 . Functionally, intra--PAG administration of a CB1 agonist enhances morphine analgesia 87 , and systemic administration of cannabinoids, along with morphine, leads to the attenuation of morphine tolerance 15, 69, 87 .
Endocannabinoids also possess potent anti--inflammatory properties 22 , which would likely block the activation of glia. Indeed, systemic administration of the cannabinoid receptor agonist WIN 55,212--2 prevents microglia and astrocyte activation, and decreases the release of the proinflammatory cytokines interleukin (IL)--1β, IL--6 and tumor necrosis factor (TNF)--α in the spinal cord 10 .
In the present study, no glia activation was noted following administration of CFA alone. These results are in contrast with previous reports that peripheral pain, including CFA 13, 50, 62, 72 , peripheral neuropathy 16, 21, 27, 62, 73, 74, 83 , formalin 45 , and spinal nerve ligation 30 induce significant glia activation within the spinal cord. However, given the roles of the spinal cord and PAG in pain facilitation and pain modulation, respectively, it is not entirely surprising that there would be differential pain--induced regulation of glial activation in these two sites. Together, these studies suggest that inflammation elicits differential glial responses in a CNS region--dependent manner, and prevents morphine--induced increases in vlPAG glial cell activity.
How opioids activate glia
Opioid hyperalgesia is still observed in neuronal opioid receptor (mu, delta, and kappa) knockout mice 36 , suggesting that the anti--analgesic affects of morphine (e.g., anti--analgesia and tolerance) are mediated by non--neuronal opioid receptors. Indeed, it was recently discovered that morphine analgesia is modulated not only by classical neuronal opioid receptors but also by non--classical glial receptor activity 34 . Opioids have been shown to bind to Toll--like receptor 4 (TLR4) 34 , an innate immune receptor located on microglia and astrocytes, and an abundance of evidence has accumulated indicating that TLR4 activity opposes morphine analgesia 34, 86 .
Functionally, animals that receive TLR4 antagonism, as well as TLR4 knockout mice, exhibit increased responsiveness to the analgesic properties of acute morphine administration 86 .
Similarly, systemic administration of TLR4 antagonists attenuates morphine tolerance 34 . To date, the specific role of TLR4 in morphine tolerance development has not been elucidated.
However, given our findings that the development of morphine tolerance correlates with increased vlPAG glial cell activation, and the evidence showing that TLR4 is expressed on rat PAG glia 12, 40 , future studies investigating the potential role of vlPAG TLR4 in the development of morphine tolerance are warranted.
Conclusions
There is extensive literature supporting a critical role for glial cell activation in the development of morphine tolerance. Our findings that increased vlPAG glial activity is concurrent with the development of morphine tolerance, and that pain inhibits both vlPAG glial reactivity and morphine tolerance development suggests that vlPAG glia play a significant role in the development of morphine tolerance. Taken together, our results may provide a direct neurobiological mechanism whereby chronic inflammatory pain attenuates the development of morphine tolerance, and implicate vlPAG glial cells as key regulators of this phenomenon. 
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